| Revenue Growth | Animal Health 3%, Mineral Nutrition 17%, Performance Products 16% growth. |
|---|---|
| Mgmt Confidence | Cautiously optimistic; maintained guidance despite Q1 beat due to expense timing. |
| Demand Visibility | Strong demand in MFA North America/Asia; lower poultry demand in North America. |
| Margin Trends | Adjusted EBITDA grew 4%; Animal Health EBITDA down $1M on SG&A. |
| Op. Leverage | Higher SG&A offset gross profit improvements; corporate expenses decreased $0.6M. |
| Pricing Power | Increased average selling prices for zinc oxide, copper, and trace minerals. |
| Vol vs Price | Growth driven by both increased demand and higher average selling prices. |
| Segment Growth | Mineral Nutrition outperformed at 17%; Animal Health lagged at 3%. |
| New Clients | Transition of Tier 3 markets (Canada, Europe) from Zoetis back to Phibro. |
| Capex & Debt | $64M CapEx; $740M total debt; net leverage ratio 2.6 times. |
| Regulatory | $5.2M sales decrease in Brazil due to Virginia Myson regulatory developments. |
| Commentary | Focus on debt flexibility and returns to shareholders while integrating Zoetis portfolio. |
Growth
Consolidated sales rose 6% to $386.8M; Mineral Nutrition grew 17%, Performance Products 16%.
Outlook
FY2027 guidance: Revenue $1.55B-$1.6B (4% growth), Adjusted Net Income $140M-$147M (9% growth).
Risks
Management pivoted on EBITDA guidance raise, citing shifted expenses and Brazil regulatory delays.
The company's earnings call, NASDAQ: PAHC, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Phibro Animal Health Corp: key numbers
- Share price
- $35.02Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Phibro Animal Health Corp
All →Phibro Animal Health Financial Results
Phibro Animal Health reported Q1 2027 net sales of $386.8 million, a 6% increase year-over-year, driven by growth in Mineral Nutrition and Performance Products. The company maintained its full-year fiscal 2027 guidance despite regulatory headwinds for virginiamycin in Brazil. Additionally, shareholders ratified the election of three Class I directors and the appointment of PwC as auditors at the annual meeting.
- Term
- Q1 2027
“First quarter results exceeded our expectations and grew on top of a strong first quarter last year. The outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products while our core Animal Health business delivered sales in line with our plan and Adjusted EBITDA ahead of plan, including the benefit of certain costs that shifted into the second quarter.”
Dani Bendheim, President and Chief Executive Officer
“Improving working capital and cash conversion is a top priority, and we are committed to delivering meaningful progress during fiscal 2027.”
Dani Bendheim, President and Chief Executive Officer
Phibro Animal Health Q1 2026 Results: Net Income $29.5M, Up 11.3% YoY
Phibro Animal Health Corp reported net sales of $386.8 million for the quarter ended September 30, 2026, a 6% increase compared to the prior year. Net income rose to $29.5 million ($0.72 per diluted share) from $26.5 million, driven by higher sales volume and improved foreign currency impacts despite an increase in selling, general, and administrative expenses.
- Key figure
- Net income $29.5M · +11.3% YoY
Phibro Animal Health Dividend
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on December 16, 2026, to stockholders of record as of November 25, 2026.